Safety and efficacy of molnupiravir in SARS‐CoV‐2‐infected patients: A real‐life experience

Since the start of the severe acute respiratory syndrome coronavirus‐2 (SARS‐CoV‐2) pandemic, several treatments have been proposed to cure coronavirus disease 2019 (COVID‐19) and prevent it. Molnupiravir is a ribonucleoside prodrug of N‐hydroxycytidine with an in vitro and in vivo activity against...

Descripción completa

Detalles Bibliográficos
Autores principales: De Vito, Andrea, Colpani, Agnese, Bitti, Alessandra, Zauli, Beatrice, Meloni, Maria Chiara, Fois, Marco, Denti, Lucia, Bacciu, Sara, Marcia, Claudia, Maida, Ivana, Babudieri, Sergio, Madeddu, Giordano
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Short Communications
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9349683/
https://www.ncbi.nlm.nih.gov/pubmed/35855627
http://dx.doi.org/10.1002/jmv.28011

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9349683/
https://www.ncbi.nlm.nih.gov/pubmed/35855627
http://dx.doi.org/10.1002/jmv.28011

Ejemplares similares